Cargando…

Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients

BACKGROUND: Myelin oligodendrocyte glycoprotein (MOG) antibody disease (MOG-AD) is recognized as a distinct nosological entity. IgG antibodies against MOG (MOG-Ab) overlap with neuromyelitis optica spectrum disorders (NMOSD) phenotype in adults. However, an increasing number of clinical phenotypes h...

Descripción completa

Detalles Bibliográficos
Autores principales: Held, Friederike, Kalluri, Sudhakar Reddy, Berthele, Achim, Klein, Ana-Katharina, Reindl, Markus, Hemmer, Bernhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246507/
https://www.ncbi.nlm.nih.gov/pubmed/34262784
http://dx.doi.org/10.1177/20552173211022767
_version_ 1783716327757709312
author Held, Friederike
Kalluri, Sudhakar Reddy
Berthele, Achim
Klein, Ana-Katharina
Reindl, Markus
Hemmer, Bernhard
author_facet Held, Friederike
Kalluri, Sudhakar Reddy
Berthele, Achim
Klein, Ana-Katharina
Reindl, Markus
Hemmer, Bernhard
author_sort Held, Friederike
collection PubMed
description BACKGROUND: Myelin oligodendrocyte glycoprotein (MOG) antibody disease (MOG-AD) is recognized as a distinct nosological entity. IgG antibodies against MOG (MOG-Ab) overlap with neuromyelitis optica spectrum disorders (NMOSD) phenotype in adults. However, an increasing number of clinical phenotypes have been reported to be associated with MOG-Ab. OBJECTIVE: To investigate the seroprevalence of MOG-Ab under consideration of demographics, disease entities and time course in a large cohort of unselected neurological patients. METHODS: Blood samples of 2.107 consecutive adult neurologic patients admitted to our department between 2016-2017 were tested for MOG-Ab using a cell-based assay. MOG-Ab persistence was analyzed in follow-up samples. External validation was performed in two independent laboratories. RESULTS: We found MOG-Ab in 25 of 2.107 (1.2%) patients. High antibody ratios were mostly associated with NMOSD and MOG-AD phenotype (5/25). Low ratios occurred in a wide range of neurological diseases, predominantly in other demyelinating CNS diseases (5/25) and stroke (6/25). MOG-Ab persistence over time was not confined to NMOSD and MOG-AD phenotype. CONCLUSION: The present study demonstrates the occurrence of MOG-Ab in a wide range of neurological diseases. Only high MOG-Ab ratios were associated with a defined clinical phenotype, but low MOG-Ab ratios were not. The diagnostic value of low MOG-Ab is thus highly limited.
format Online
Article
Text
id pubmed-8246507
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-82465072021-07-13 Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients Held, Friederike Kalluri, Sudhakar Reddy Berthele, Achim Klein, Ana-Katharina Reindl, Markus Hemmer, Bernhard Mult Scler J Exp Transl Clin Original Research Paper BACKGROUND: Myelin oligodendrocyte glycoprotein (MOG) antibody disease (MOG-AD) is recognized as a distinct nosological entity. IgG antibodies against MOG (MOG-Ab) overlap with neuromyelitis optica spectrum disorders (NMOSD) phenotype in adults. However, an increasing number of clinical phenotypes have been reported to be associated with MOG-Ab. OBJECTIVE: To investigate the seroprevalence of MOG-Ab under consideration of demographics, disease entities and time course in a large cohort of unselected neurological patients. METHODS: Blood samples of 2.107 consecutive adult neurologic patients admitted to our department between 2016-2017 were tested for MOG-Ab using a cell-based assay. MOG-Ab persistence was analyzed in follow-up samples. External validation was performed in two independent laboratories. RESULTS: We found MOG-Ab in 25 of 2.107 (1.2%) patients. High antibody ratios were mostly associated with NMOSD and MOG-AD phenotype (5/25). Low ratios occurred in a wide range of neurological diseases, predominantly in other demyelinating CNS diseases (5/25) and stroke (6/25). MOG-Ab persistence over time was not confined to NMOSD and MOG-AD phenotype. CONCLUSION: The present study demonstrates the occurrence of MOG-Ab in a wide range of neurological diseases. Only high MOG-Ab ratios were associated with a defined clinical phenotype, but low MOG-Ab ratios were not. The diagnostic value of low MOG-Ab is thus highly limited. SAGE Publications 2021-06-25 /pmc/articles/PMC8246507/ /pubmed/34262784 http://dx.doi.org/10.1177/20552173211022767 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Paper
Held, Friederike
Kalluri, Sudhakar Reddy
Berthele, Achim
Klein, Ana-Katharina
Reindl, Markus
Hemmer, Bernhard
Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients
title Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients
title_full Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients
title_fullStr Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients
title_full_unstemmed Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients
title_short Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients
title_sort frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients
topic Original Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246507/
https://www.ncbi.nlm.nih.gov/pubmed/34262784
http://dx.doi.org/10.1177/20552173211022767
work_keys_str_mv AT heldfriederike frequencyofmyelinoligodendrocyteglycoproteinantibodiesinalargecohortofneurologicalpatients
AT kallurisudhakarreddy frequencyofmyelinoligodendrocyteglycoproteinantibodiesinalargecohortofneurologicalpatients
AT bertheleachim frequencyofmyelinoligodendrocyteglycoproteinantibodiesinalargecohortofneurologicalpatients
AT kleinanakatharina frequencyofmyelinoligodendrocyteglycoproteinantibodiesinalargecohortofneurologicalpatients
AT reindlmarkus frequencyofmyelinoligodendrocyteglycoproteinantibodiesinalargecohortofneurologicalpatients
AT hemmerbernhard frequencyofmyelinoligodendrocyteglycoproteinantibodiesinalargecohortofneurologicalpatients